Multivariate analysis on the impact of HLA-DPB1 mismatches on transplantation outcome in patients with thalassemia
Variable . | Relative risk (95% CI) . | P . |
|---|---|---|
| Risk of rejection | ||
| Patient sex | ||
| Male vs. female | 1.64 (0.29-9.34) | NS |
| Donor age | ||
| 35 y or older vs younger than 35 y | 2.57 (0.45-14.59) | .29 |
| Conditioning regimen | ||
| BU + TT + CY vs BU + CY | 0.12 (0.01-1.25) | .08 |
| BU + TT + FLU vs BU + CY | 0.88 (0.23-1.90) | NS |
| Use of ATG | ||
| Yes vs no | 0.77 (0.15-4.10) | NS |
| HLA-DPB1 mismatch | ||
| Nonpermissive mismatch in GvH direction vs matched + permissive | 3.98 (0.35-45.24) | .27 |
| Nonpermissive mismatch in HvG direction vs matched + permissive | 7.42 (1.29-42.68) | .02 |
| Grade II–IV aGvHD* | ||
| Sex mismatch in HvG direction | ||
| Male donor and female recipient vs others | 1.48 (0.62-3.52) | .37 |
| Donor age | ||
| 35 y or older vs younger than 35 y | 2.13 (0.91-4.98) | .08 |
| HCMV serology, donor→recipient | ||
| Negative→positive vs negative→negative | 0.49 (0.09-2.75) | .42 |
| Positive→negative vs negative→negative | 0.85 (0.18-4.06) | NS |
| Positive→positive vs negative→negative | 1.63 (0.42-6.31) | .48 |
| Cell dose infused, × 108/kg | ||
| 5 or more vs less than 5 | 2.40 (0.94-5.55) | .07 |
| HLA-DPB1 mismatch | ||
| Nonpermissive mismatch in GvH direction vs matched + permissive | 2.87 (0.83-9.94) | .10 |
| Nonpermissive mismatch in HvG direction vs matched + permissive | 2.21 (0.85-5.78) | .11 |
| TFS probability | ||
| Patient sex | ||
| Male vs female | 3.16 (0.96-10.40) | .06 |
| Sex mismatch in GvH direction | ||
| Female donor and male recipient vs others | 1.08 (0.28-4.14) | NS |
| Patient age at HSCT | ||
| 15 y or older or younger than 15 y | 0.65 (0.15-2.81) | NS |
| Donor age | ||
| 35 y or older vs younger than 35 y | 3.21 (1.05-9.83) | .04 |
| Pesaro class | ||
| Class 1 | — | — |
| Class 2 | 0.79 (0.13-4.64) | NS |
| Class 3 | 3.17 (0.41-24.65) | .27 |
| HCMV serology, donor→recipient | ||
| Negative→positive vs negative→negative | 3.89 (0.54-28.30) | .18 |
| Positive→negative vs negative→negative | 0.29 (0.02-3.84) | .35 |
| Positive→positive vs negative→negative | 2.54 (0.40-16.24) | .32 |
| Use of ATG | ||
| Yes vs no | 1.97 (0.44-8.79) | .38 |
| Cell dose infused, × 108/kg | ||
| 5 or greater vs less than 5 | 0.39 (0.11-1.34) | .13 |
| HLA-DPB1 mismatch | ||
| Nonpermissive mismatch in GvH direction vs matched + permissive | 1.48 (0.34-6.51) | NS |
| Nonpermissive mismatch in HvG direction vs matched + permissive | 5.15 (1.58-16.82) | .01 |
Variable . | Relative risk (95% CI) . | P . |
|---|---|---|
| Risk of rejection | ||
| Patient sex | ||
| Male vs. female | 1.64 (0.29-9.34) | NS |
| Donor age | ||
| 35 y or older vs younger than 35 y | 2.57 (0.45-14.59) | .29 |
| Conditioning regimen | ||
| BU + TT + CY vs BU + CY | 0.12 (0.01-1.25) | .08 |
| BU + TT + FLU vs BU + CY | 0.88 (0.23-1.90) | NS |
| Use of ATG | ||
| Yes vs no | 0.77 (0.15-4.10) | NS |
| HLA-DPB1 mismatch | ||
| Nonpermissive mismatch in GvH direction vs matched + permissive | 3.98 (0.35-45.24) | .27 |
| Nonpermissive mismatch in HvG direction vs matched + permissive | 7.42 (1.29-42.68) | .02 |
| Grade II–IV aGvHD* | ||
| Sex mismatch in HvG direction | ||
| Male donor and female recipient vs others | 1.48 (0.62-3.52) | .37 |
| Donor age | ||
| 35 y or older vs younger than 35 y | 2.13 (0.91-4.98) | .08 |
| HCMV serology, donor→recipient | ||
| Negative→positive vs negative→negative | 0.49 (0.09-2.75) | .42 |
| Positive→negative vs negative→negative | 0.85 (0.18-4.06) | NS |
| Positive→positive vs negative→negative | 1.63 (0.42-6.31) | .48 |
| Cell dose infused, × 108/kg | ||
| 5 or more vs less than 5 | 2.40 (0.94-5.55) | .07 |
| HLA-DPB1 mismatch | ||
| Nonpermissive mismatch in GvH direction vs matched + permissive | 2.87 (0.83-9.94) | .10 |
| Nonpermissive mismatch in HvG direction vs matched + permissive | 2.21 (0.85-5.78) | .11 |
| TFS probability | ||
| Patient sex | ||
| Male vs female | 3.16 (0.96-10.40) | .06 |
| Sex mismatch in GvH direction | ||
| Female donor and male recipient vs others | 1.08 (0.28-4.14) | NS |
| Patient age at HSCT | ||
| 15 y or older or younger than 15 y | 0.65 (0.15-2.81) | NS |
| Donor age | ||
| 35 y or older vs younger than 35 y | 3.21 (1.05-9.83) | .04 |
| Pesaro class | ||
| Class 1 | — | — |
| Class 2 | 0.79 (0.13-4.64) | NS |
| Class 3 | 3.17 (0.41-24.65) | .27 |
| HCMV serology, donor→recipient | ||
| Negative→positive vs negative→negative | 3.89 (0.54-28.30) | .18 |
| Positive→negative vs negative→negative | 0.29 (0.02-3.84) | .35 |
| Positive→positive vs negative→negative | 2.54 (0.40-16.24) | .32 |
| Use of ATG | ||
| Yes vs no | 1.97 (0.44-8.79) | .38 |
| Cell dose infused, × 108/kg | ||
| 5 or greater vs less than 5 | 0.39 (0.11-1.34) | .13 |
| HLA-DPB1 mismatch | ||
| Nonpermissive mismatch in GvH direction vs matched + permissive | 1.48 (0.34-6.51) | NS |
| Nonpermissive mismatch in HvG direction vs matched + permissive | 5.15 (1.58-16.82) | .01 |
Results of multivariate analysis including relative risk (RR) for rejection, grade II–IV aGvHD and mortality, 95% CI, and P values associated with HLA-DPB1 disparities.
— indicates the reference groups.
71 of 72 pairs were evaluable for aGvHD (45 matched + permissive, 9 nonpermissive in GvH and 17 nonpermissive in HvG direction)